Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Adaptive Biotechnologies Q3 2026 Results: Net Income $2.88M, Down 69.9% YoY

Adaptive Biotechnologies reported a net loss of $57.2 million for the first nine months of 2026, compared to a $45.9 million loss in the prior year period, impacted by a $23.7 million loss on revenue interest liability extinguishment. Despite the year-to-date loss, the company achieved a quarterly net income of $2.9 million in Q3 2026, though revenue for the quarter decreased to $83.9 million from $94.0 million year-over-year.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue83.994.0
Net income2.99.5
EPS (diluted, $ a share)$0.02$0.06

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year-69.9%
Revenue, year on year-10.7%
Operating margin-0.5%
Source

10-Q filed with the SEC, NASDAQ: ADPT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Adaptive Biotechnologies Corp: key numbers

Share price
$27.87Close, Nov 16
Market cap
$4.51B
Shares outstanding
161.88MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Adaptive Biotechnologies Corp

All →
7:59 PM ET Form 4
Insider Selling

Adaptive Biotechnologies President and COO Julie Rubinstein Sells $1.05M of Stock

Julie Rubinstein, President and COO, sold 35,228 shares of Adaptive Biotechnologies Corp at $28.93 to $31.22 a share (average $29.73) in 4 transactions, worth $1.05M in total between Nov 11, 2026 and Nov 13, 2026. Shares held after the trade: 377,802 (-2.9%).

Value
$1.05M
Shares
35,228
Average price
$29.73
Role
President and COO
Holding change
-2.9%
Trade date
Nov 11, 2026 to Nov 13, 2026
7:56 PM ET Form 4
Insider Selling

Adaptive Biotechnologies Chief Commercial Officer, MRD Susan Bobulsky Sells $60K of Stock

Susan Bobulsky, Chief Commercial Officer, MRD, sold 1,875 shares of Adaptive Biotechnologies Corp at $32.00 a share, worth $60K in total on Nov 11, 2026. Shares held after the trade: 387,475 (-0.5%).

Value
$60K
Shares
1,875
Price
$32.00
Role
Chief Commercial Officer, MRD
Holding change
-0.5%
Trade date
Nov 11, 2026
7:26 PM ET Form 4
Insider Selling

Adaptive Biotechnologies President and COO Julie Rubinstein Sells $709K of Stock

Julie Rubinstein, President and COO, sold 23,762 shares of Adaptive Biotechnologies Corp at $28.87 to $30.58 a share (average $29.82) in 5 transactions, worth $709K in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 377,802 (-0.5%).

Value
$709K
Shares
23,762
Average price
$29.82
Role
President and COO
Holding change
-0.5%
Trade date
Nov 9, 2026 to Nov 10, 2026
7:24 PM ET Form 4
Insider Selling

Adaptive Biotechnologies President and COO Julie Rubinstein Sells $954K of Stock

Julie Rubinstein, President and COO, sold 35,643 shares of Adaptive Biotechnologies Corp at $25.78 to $27.88 a share (average $26.78) in 7 transactions, worth $954K in total between Nov 4, 2026 and Nov 6, 2026. Shares held after the trade: 377,802 (-0.9%).

Value
$954K
Shares
35,643
Average price
$26.78
Role
President and COO
Holding change
-0.9%
Trade date
Nov 4, 2026 to Nov 6, 2026
4:16 PM ET 8-K
Financial Results

Adaptive Biotechnologies Financial Results

Adaptive Biotechnologies reported Q3 2026 financial results, achieving total company profitability ahead of expectations with $83.9 million in revenue and $2.8 million in net income. The company saw 44% growth in core MRD revenue (excluding milestones) and increased its full-year 2026 MRD revenue guidance. Management highlighted momentum in clonoSEQ testing and updated clinical guidelines for multiple myeloma as key growth drivers.

Term
Q3 2026

“Adaptive achieved total company profitability ahead of expectations in Q3 and delivered 44% growth in core MRD revenue. This momentum supports another increase in our full year outlook. Updated guidelines and a new definition of cure for multiple myeloma amplify the need for MRD testing and bolster clonoSEQ’s long-term potential.”

Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies
7:52 PM ET Form 4
Insider Selling

Adaptive Biotechnologies President and COO Julie Rubinstein Sells $929K of Stock

Julie Rubinstein, President and COO, sold 35,643 shares of Adaptive Biotechnologies Corp at $25.23 to $27.45 a share (average $26.06) in 5 transactions, worth $929K in total between Oct 30, 2026 and Nov 3, 2026. Shares held after the trade: 377,802 (-3.0%).

Value
$929K
Shares
35,643
Average price
$26.06
Role
President and COO
Holding change
-3.0%
Trade date
Oct 30, 2026 to Nov 3, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.